Evommune, Inc. (EVMN) Profit Margins
Over the twelve months to 2026-06-30, Evommune, Inc. (EVMN) had operating margin -1018.9%, net margin -946.7%, free cash flow margin -746.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EVMNEvommune, Inc.Follow EVMN — free
—
Price chart with a free account
- Market cap
- 185.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Dec, in 46 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating margin | -1000.2% | -623.6% | -1018.9% | |
| Net margin | -954.4% | -529.8% | -946.7% | |
| FCF margin | -832.6% | -589.8% | -746.5% |
USD millions · SEC XBRL
Evommune, Inc. — questions
- What is Evommune, Inc.'s operating margin?
- -1018.9% over the twelve months to 2026-06-30.
- What is Evommune, Inc.'s net profit margin?
- -946.7% over the twelve months to 2026-06-30.
Every figure on this page comes from Evommune, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.